Emerging evidence indicates that activation of STAT3 is one of the contributors to EGFR-TKI resistance, and targeted inhibition of STAT3 signaling has shown potential to circumvent therapeutic resistance both in lung cancer and other malignancies [14, 15]. Here, EGFR is linked to lung cancer.